Study analysis · Cell metabolism · 2019
Your gut bacteria might be brewing alcohol and giving you fatty liver disease, even if you don't drink a drop.
A type of gut bacteria that produces alcohol can cause fatty liver disease in mice and is found in up to 60% of human cases in one study.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people with fatty liver disease and found that many had a certain type of bacteria in their gut. Then they gave mice that bacteria and the mice got fatty liver. This shows the bacteria might be a cause, but it's not proof for people because mice are different and we don't know if other factors were at play.
What’s the bottom line?
A type of gut bacteria that makes alcohol can cause fatty liver disease, even without drinking alcohol.
How strong is this study?
We only saw a summary of the study, not the full details. It's like hearing a story with missing pages. Without knowing exactly how they picked the people, how many there were, and what other things could have caused the fatty liver, we have to be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Human causation cannot be established because the human component is observational (association) and the experimental evidence is from animal models. Causal inference in humans would require controlled human trials.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the study excerpt.
The text only contains the study abstract; full disclosure statements are missing.
Key takeaways
- 01
Found in up to 6 out of 10 people with fatty liver in China.
- 02
When given to mice, it caused fatty liver.
- 03
Removing it from gut bacteria transplants stopped the disease.
- 04
Yes, this suggests a new cause for some fatty liver cases.
Surprising findings
- Up to 60% of NAFLD patients harbored high-alcohol-producing Klebsiella pneumoniae.Commonly, NAFLD is attributed to diet and lifestyle, but this suggests a microbial cause in many cases.
Practical takeaways
Stay tuned for future research on whether targeting gut bacteria could treat NAFLD.
Full methodology not available; findings are from mice and a Chinese cohort only.
low confidenceWhy this study matters
The Alcohol-Producing Bacteria
Researchers found that a strain of Klebsiella pneumoniae, dubbed HiAlc Kpn, produces high levels of alcohol. In a Chinese cohort, this bacterium was present in up to 60% of individuals with nonalcoholic fatty liver disease (NAFLD). When given to mice, it induced NAFLD.
This suggests that some cases of fatty liver disease might be caused by bacteria making alcohol inside your gut, not by drinking.
Mouse Model Proves Causality
Oral administration of HiAlc Kpn to mice caused NAFLD. Even more striking, fecal microbiota transplant from a NASH patient with the bacteria induced NAFLD in mice, but selectively removing the bacteria before transplant prevented the disease.
This shows a direct causal link in an animal model, strengthening the hypothesis that gut bacteria can drive NAFLD.
A New Target for Treatment?
The study suggests that eliminating HiAlc Kpn from the gut could potentially prevent or treat NAFLD in some patients. However, this is based on mouse experiments and a cross-sectional human association.
It opens up possibilities for new therapies like probiotics or antibiotics targeting this specific bacterium.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A type of gut bacteria that makes alcohol can cause fatty liver disease, even without drinking alcohol.
Research results
Found in up to 6 out of 10 people with fatty liver in China. When given to mice, it caused fatty liver. Removing it from gut bacteria transplants stopped the disease.
What this means - more context
Yes, this suggests a new cause for some fatty liver cases.
To investigate whether high-alcohol-producing Klebsiella pneumoniae (HiAlc Kpn) in the gut microbiome can cause nonalcoholic fatty liver disease (NAFLD).
HiAlc Kpn was found in up to 60% of NAFLD patients in a Chinese cohort. Oral administration of HiAlc Kpn or fecal microbiota transplant containing it induced NAFLD in mice, while selective elimination prevented it, suggesting a causal role for bacterial alcohol production in some NAFLD cases.
Methods Used
Human cohort association study in China; mouse experiments with oral gavage of HiAlc Kpn clinical isolates and fecal microbiota transplant (FMT) from a NASH patient; selective elimination of HiAlc Kpn before FMT.
Main Finding
HiAlc Kpn is associated with up to 60% of NAFLD in a Chinese cohort and induces NAFLD in mice, with selective elimination preventing disease transmission via FMT.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Human cohort is cross-sectional, not longitudinal
- •Sample size and detailed methods not specified in abstract
Surprising Findings
Up to 60% of NAFLD patients harbored high-alcohol-producing Klebsiella pneumoniae.
Commonly, NAFLD is attributed to diet and lifestyle, but this suggests a microbial cause in many cases.
Practical Takeaways
Stay tuned for future research on whether targeting gut bacteria could treat NAFLD.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at people with fatty liver disease and found that many had a certain type of bacteria in their gut. Then they gave mice that bacteria and the mice got fatty liver. This shows the bacteria might be a cause, but it's not proof for people because mice are different and we don't know if other factors were at play.
Strengths
- Identification of a potential microbial driver for NAFLD.
- Animal experiments (oral gavage and FMT) provide mechanistic support.
- Use of a specific cohort to show association in humans.
Weaknesses
- Full methodology not available - based on abstract only.
- Human study design is unclear (likely cross-sectional or case-control, not a cohort).
- No information on sample size, selection criteria, or confounding control.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A type of gut bacteria that makes alcohol can cause fatty liver disease, even without drinking alcohol.
Research results
Found in up to 6 out of 10 people with fatty liver in China. When given to mice, it caused fatty liver. Removing it from gut bacteria transplants stopped the disease.
What this means - more context
Yes, this suggests a new cause for some fatty liver cases.
To investigate whether high-alcohol-producing Klebsiella pneumoniae (HiAlc Kpn) in the gut microbiome can cause nonalcoholic fatty liver disease (NAFLD).
HiAlc Kpn was found in up to 60% of NAFLD patients in a Chinese cohort. Oral administration of HiAlc Kpn or fecal microbiota transplant containing it induced NAFLD in mice, while selective elimination prevented it, suggesting a causal role for bacterial alcohol production in some NAFLD cases.
Methods Used
Human cohort association study in China; mouse experiments with oral gavage of HiAlc Kpn clinical isolates and fecal microbiota transplant (FMT) from a NASH patient; selective elimination of HiAlc Kpn before FMT.
Main Finding
HiAlc Kpn is associated with up to 60% of NAFLD in a Chinese cohort and induces NAFLD in mice, with selective elimination preventing disease transmission via FMT.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Human cohort is cross-sectional, not longitudinal
- •Sample size and detailed methods not specified in abstract
Surprising Findings
Up to 60% of NAFLD patients harbored high-alcohol-producing Klebsiella pneumoniae.
Commonly, NAFLD is attributed to diet and lifestyle, but this suggests a microbial cause in many cases.
Practical Takeaways
Stay tuned for future research on whether targeting gut bacteria could treat NAFLD.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at people with fatty liver disease and found that many had a certain type of bacteria in their gut. Then they gave mice that bacteria and the mice got fatty liver. This shows the bacteria might be a cause, but it's not proof for people because mice are different and we don't know if other factors were at play.
Strengths
- Identification of a potential microbial driver for NAFLD.
- Animal experiments (oral gavage and FMT) provide mechanistic support.
- Use of a specific cohort to show association in humans.
Weaknesses
- Full methodology not available - based on abstract only.
- Human study design is unclear (likely cross-sectional or case-control, not a cohort).
- No information on sample size, selection criteria, or confounding control.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
We only saw a summary of the study, not the full details. It's like hearing a story with missing pages. Without knowing exactly how they picked the people, how many there were, and what other things could have caused the fatty liver, we have to be careful about trusting the results too much.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Human causation cannot be established because the human component is observational (association) and the experimental evidence is from animal models. Causal inference in humans would require controlled human trials.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the study excerpt.
The text only contains the study abstract; full disclosure statements are missing.